Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
Molnupiravir in COVID-19: A systematic review of literature
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
S Singla, S Goyal - Bulletin of the National Research Centre, 2022 - Springer
Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
Why molnupiravir fails in hospitalized patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
[HTML][HTML] Molnupiravir as an early treatment for COVID-19: a real life study
M Pontolillo, C Ucciferri, P Borrelli, M Di Nicola… - Pathogens, 2022 - mdpi.com
Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug
against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials …
against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials …
New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19
RL Atmar, N Finch - Antimicrobial Agents and Chemotherapy, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …